Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.61 |
| ▸ | BACE2 | Q9Y5Z0 | 19/20 | 0.61 |
| ▸ | CTSD | P07339 | 17/20 | 0.61 |
| ▸ | REN | P00797 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22029322 | 0.93 | BACE1 (0.53) | BACE1BACE2CTSDREN | |
| SCHEMBL22028524 | 0.91 | BACE1 (0.71) | BACE1BACE2CTSDREN | |
| SCHEMBL22029324 | 0.87 | BACE1 (0.46) | BACE1BACE2CTSDREN | |
| SCHEMBL22029328 | 0.86 | BACE1 (0.53) | BACE1BACE2CTSDREN | |
| SCHEMBL22026010 | 0.86 | BACE1 (0.62) | BACE1BACE2CTSDREN | |
| SCHEMBL22026011 | 0.86 | BACE1 (0.53) | BACE1BACE2CTSDREN | |
| SCHEMBL22025976 | 0.85 | BACE1 (0.78) | BACE1BACE2CTSD | |
| SCHEMBL22029329 | 0.85 | BACE1 (0.52) | BACE1BACE2CTSD | |
| SCHEMBL22029325 | 0.85 | BACE1 (0.49) | BACE1BACE2CTSD | |
| SCHEMBL22028526 | 0.84 | BACE1 (0.63) | BACE1BACE2CTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN2 | BACE1 1/4885BACE2 2/4885CTSD 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.